The US government had put the waiver of intellectual property rights into play in order to increase vaccine production.
However, abandoning intellectual property rights is the wrong way to increase production of Covid-19 vaccines, according to Biontech CEO Uğur Şahin. "This is not a solution," Şahin said at a briefing with members of Germany’s foreign press association TODAY:
Şahin said it was important that vaccines produced in the EU were also exported to other parts of the world. He expects herd immunity to be achieved in the EU by the end of the summer. But there is little point in Europe being safe if the virus continues to ravage other regions.
Şahin expects his vaccine to be approved in China by June at the latest. There, Biontech cooperates with Fosun Pharma; outside the People's Republic, Biontech works with the US pharmaceutical company Pfizer.
Regarding reports of cases of heart muscle inflammation from Israel after vaccination with its Covid-19 vaccine, Şahin said the company was investigating them. So far, however, there are no indications of an unusual occurrence and clustered cases of heart muscle inflammation.
“I can imagine a production network in South America and for Africa,” Sahin said at a briefing with members of Germany’s foreign press association. “We are also talking about African production sites.”
Though BioNTech and its U.S. partner Pfizer Inc. have committed to make 2.5 billion doses of their two-shot vaccine this year, the vast majority are tied up in lucrative contracts with the world’s wealthiest countries. Africa trails the rest of the world in accessing the shots it needs to immunize its more than 1 billion residents. Globally, countries with the highest incomes are getting vaccinated about 25 times faster than those with the lowest, Bloomberg’s Vaccine Tracker shows.
Source: translated from a report @ Spiegel
, marked quote from Bloomberg